PVLA
NASDAQPalvella Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$157.51+5.78 (+3.81%)
01:45 PM07:45 PM
News · 26 weeks80-25%
2026-01-182026-07-12
Mix3790d
- Insider12(32%)
- Other11(30%)
- SEC Filings10(27%)
- Offering2(5%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $642,191 worth of shares (4,302 units at $149.28) as part of a pre-agreed trading plan (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- INSIDERSEC Form 4 filed by Director Pauls Matthew4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pauls Matthew3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- PRPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease experience, including executive and Board roles at Savara Inc. (NASDAQ:SVRA), Soleno Therapeutics (NASDAQ:SLNO), Strongbridge Biopharma (NASDAQ:SBBP) and Insmed Incorporated (NASDAQ:INSM) WAYNE, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which th
- PRPalvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsFDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy and Fast Track designations for QTORIN™ rapamycin, providing an expedited development and review pathway based on its potential to address a serious unmet medical need Palvella remains on track to complete the NDA submission in the second half of 2026 while accelerating U.S. launch readiness for a potential standalone commercial launch of QTORIN™ rapamycin in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy an
- INSIDERChief Operating Officer Goin Kathleen sold $476,373 worth of shares (4,302 units at $110.73) as part of a pre-agreed trading plan and exercised 4,302 shares at a strike of $8.11 (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- PRFDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic MalformationsFDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on track to complete the NDA submission in the second half of 2026 QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare
- INSIDERCFO, Treasurer Korenberg Matthew E exercised 1,000 shares at a strike of $13.60 (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- INSIDERSEC Form 4 filed by Director Kiritsy Christopher P4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Jenkins George M4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Heron Elaine J4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Doux John4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis Todd C4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- INSIDERSEC Form 4 filed by Director Wessel Tadd S.4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- PRResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of DirectorsBERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell therapy modality where living, genetically engineered bacteria continuously produce protein therapeutics for skin diseases, today announced the appointment of John D. Doux, M.D., M.B.A., to its Board of Directors. "We are thrilled to welcome John to our Board as ResVita prepares to enter the clinic with RVB-003 in Netherton Syndrome and expands our continuous protein therapy platform across a broad range of chronic and rare skin diseases," said Amin Zargar, Ph.D., Chief Executive Officer and Co-Founder of ResVita Bio. "John is a respected voice in rare skin disease drug development w
- PRPalvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic MalformationsPalvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection, functional impairment, and significant daily burden for patients and families QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing n
- PRPalvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET. A live webcast of the fireside chat will be available on the Events and Present
- PRPalvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant genetic skin disease affecting an estimated more than 50,000 diagnosed patients in the U.S., with no FDA-approved therapies Palvella plans to initiate a Phase 2 clinical trial of QTORIN™ pitavastatin in DSAP in the second half of 2026 WAYNE, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering f
- INSIDERChief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $475,631 worth of shares (4,302 units at $110.56) as part of a pre-agreed trading plan (SEC Form 4)4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
- PRPalvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular MalformationsIn SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) scale at Week 24, with a mean improvement of +2.46 (p<0.001) 87% of participants (20/23) in SELVA with moderate or worse leaking/bleeding at baseline were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the mLM-IGA Leaking/Bleeding at Week 24, with a mean improvement of +2.48 (p<0.001) 100% of SELVA participants who completed the efficacy evaluation period (43/43) were at least somewhat satisfied with QTORIN™ rapamycin on the TSQM-9 overall satisfaction item at We
- SECPalvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
PVLA FAQ
5 questionsWhere does PVLA stock trade?
Palvella Therapeutics Inc. (PVLA) is listed on NASDAQ.What sector and industry is PVLA in?
Palvella Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PVLA?
Palvella Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stephens: Overweight on 2026-05-12.What companies are similar to PVLA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PVLA side-by-side with any of them on Quantisnow.How can I track PVLA on Quantisnow?
Quantisnow aggregates Palvella Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PVLA to receive live email and push alerts on every new disclosure.